Equity Profile

CTMX

CytomX Therapeutics, Inc.

Health CareBiotechnology$805.5M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies using its proprietary Probody platform....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies using its proprietary Probody platform. As part of the health care sector, it aims to create targeted treatments that can improve patient outcomes while minimizing side effects, which is crucial in the ongoing fight against cancer.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, beating expectations by 29.58%. However, the stock fell 3.15% the following day, indicating mixed market reactions.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, especially given the lack of analyst estimates and management guidance.

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or announce new partnerships, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports wider losses or delays in its drug development pipeline, it could further dampen investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the clinical trials for its lead drug candidates?

Updates on clinical trials are crucial as they can significantly influence investor confidence and stock performance.

Are there any new partnerships or collaborations that could enhance the pipeline?

New partnerships can provide additional resources and validation for the company's drug development efforts, impacting future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent advancements in CytomX's drug pipeline, which could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a 37.5% move, suggesting traders expect significant volatility, which may not align with the actual performance.

CytomX has a history of surprising on the upside, with a 63% EPS beat rate in recent quarters.

Key Risk

If the clinical trial updates are more favorable than anticipated, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of delays and financial performance.

Bull Confirmed If

Demonstrating a clear path to commercialization for at least one drug candidate would support a bullish outlook.

Bear Confirmed If

Reporting a delay in clinical trials or higher-than-expected losses would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise by around 25.2%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response as investors await further clarity from management commentary.

Miss

If the company misses expectations, history suggests a potential decline of about 15.16%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results for lead drug candidates.
2Any announcements regarding new partnerships or collaborations.
3Management's commentary on financial outlook and cost management.
4Insights into market demand for their therapies.
5Details on regulatory progress for their drug candidates.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies using its proprietary Probody platform....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, beating expectations by 29.58%. However, the stock fell 3.15% the following day, indicating mixed market reactions.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, especially given the lack of analyst estimates and management guidance.

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or announce new partnerships, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports wider losses or delays in its drug development pipeline, it could further dampen investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the clinical trials for its lead drug candidates?

Updates on clinical trials are crucial as they can significantly influence investor confidence and stock performance.

Are there any new partnerships or collaborations that could enhance the pipeline?

New partnerships can provide additional resources and validation for the company's drug development efforts, impacting future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent advancements in CytomX's drug pipeline, which could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a 37.5% move, suggesting traders expect significant volatility, which may not align with the actual performance.

CytomX has a history of surprising on the upside, with a 63% EPS beat rate in recent quarters.

Key Risk

If the clinical trial updates are more favorable than anticipated, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of delays and financial performance.

Bull Confirmed If

Demonstrating a clear path to commercialization for at least one drug candidate would support a bullish outlook.

Bear Confirmed If

Reporting a delay in clinical trials or higher-than-expected losses would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise by around 25.2%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response as investors await further clarity from management commentary.

Miss

If the company misses expectations, history suggests a potential decline of about 15.16%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results for lead drug candidates.
2Any announcements regarding new partnerships or collaborations.
3Management's commentary on financial outlook and cost management.
4Insights into market demand for their therapies.
5Details on regulatory progress for their drug candidates.